Breast Cancer
News
Does adjuvant oophorectomy improve survival in BRCA1 or BRCA2 mutation carriers with breast cancer?
Yes. Oophorectomy is associated with a reduction in mortality in women with a BRCA1 mutation who have breast cancer, according to this...
News
Atypical hyperplasia of the breast: Cancer risk-reduction strategies
Women with atypical hyperplasia are at increased risk for breast cancer. We need to characterize that risk for patients and ensure appropriate...
News
Insurance, location, income drive breast cancer surgery choices
Travel distance to treatment facilities of more than 28 km is associated with a lower likelihood of having breast-conserving surgery for early...
News
ASCO: HR-deficient breast cancers more likely to respond to carboplatin
Key clinical point: HR deficiency is a biomarker for benefit from neoadjuvant chemotherapy in women with TNBC. Major finding: Women with HR-...
Video
VIDEO: Consider cost in anastrozole vs. tamoxifen for DCIS
Dr. Richard Margolese discusses the costs and side effects of anastrozole vs. tamoxifen after postmenopausal ductal carcinoma in situ.
News
Obesity boosts postmenopausal breast cancer risk
Key clinical point: Women who are overweight and obese have a significantly higher risk of postmenopausal invasive breast cancer, particularly...
Conference Coverage
ASCO: Adjuvant denosumab halves fracture risk for breast cancer patients on AIs
Key clinical point: Denosumab reduces the risk of clinical fractures in postmenopausal women taking AIs for early breast cancer. Major finding:...
News
ASCO: Etirinotecan pegol prolongs life for women with brain, liver mets of breast cancer
Key clinical point: Etirinotecan pegol is efficacious in patients with brain or liver metastases of breast cancer. Major finding: Etirinotecan...
Conference Coverage
ASCO: Omitting adjuvant radiation after pCR ups locoregional recurrence risk
Key clinical point: Adjuvant radiation therapy improves locoregional recurrence–free survival after neoadjuvant chemo and surgery for breast...
News
Advanced breast cancer: paclitaxel bests nab-paclitaxel, ixabepilone
Key clinical point: Newly developed agents nab-paclitaxel and ixabepilone both failed to outperform paclitaxel against advanced breast cancer....